June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Treat and Extend in the treatment of exsudative age related macular degeneration
Author Affiliations & Notes
  • Bianca Apitzsch
    Eye Center Johannisplatz, Leipzig, Saxony, Germany
  • Lisa Fechner
    Department of Ophthalmology, University Hospital Halle (Saale), Halle (Saale), Saxony-Anhalt, Germany
  • Caroline Bormann
    Eye Center Halle (Saale), Halle (Saale), Saxony Anhalt, Germany
  • Anke Habermann
    Eye Center Halle (Saale), Halle (Saale), Saxony Anhalt, Germany
  • Ute Hammer
    Eye Center Halle (Saale), Halle (Saale), Saxony Anhalt, Germany
  • Thomas Hammer
    Department of Ophthalmology, University Hospital Halle (Saale), Halle (Saale), Saxony-Anhalt, Germany
    Eye Center Halle (Saale), Halle (Saale), Saxony Anhalt, Germany
  • Footnotes
    Commercial Relationships   Bianca Apitzsch, None; Lisa Fechner, None; Caroline Bormann, None; Anke Habermann, None; Ute Hammer, None; Thomas Hammer, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3197. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Bianca Apitzsch, Lisa Fechner, Caroline Bormann, Anke Habermann, Ute Hammer, Thomas Hammer; Treat and Extend in the treatment of exsudative age related macular degeneration. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3197.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : The aim of this study was to assess the efficacy of the "treat and extend" scheme in patients with age related macular degeneration, using Ranibizumab (Lucentis®) Adalimumab (Eylea®) and/or Bevacizumab (Avastin®) .

Methods : In a retrospective study we identified patients who were treated with Anti VEGF due to exsudative age related macular degeneration (AMD) between June 2014 and September 2016, using the "treat and extend" scheme. Outcome measures included the best corrected visual acuity (BCVA), the evaluation of optical coherence tomography (OCT) including the reduction of macular edema (ME) if present and the individual treatment interval.

Results : 116 eyes of 113 patients (65 female, 48 male) with an average age of 77.3 years (range 43-92 years) were treated with Ranibizumab (19 patients), Adalimumab (60 patients) or Bevacizumab (10 patients) alone. Four patients received Ranibizumab and Bevacizumab, six patients Adalimumab and Bevacizumab, 15 patients received with Ranibizumab and Adalimumab and 2 patients were treated with all of them. Altogether patients were treated over an average follow -up period of 75.1 weeks (range 19-119 weeks). The average individual treatment interval was 8.9 weeks. A reduction of macular thickness from 332 µm before the treatment to 307 µm at the last follow up was found. Before and after the treat and extend treatment the median BCVA was 0.4.

Conclusions : In this retrospective study we could see an improvement in macular thickness and a stable BCVA using the "treat and extend" scheme in patients with exsudative age related macular degeneration using these three substances.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×